Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01437
|
|||||
| Drug Name |
UCN-01
|
|||||
| Synonyms |
UCN; UCN01; Ucn 01; KRX-0601; KW-2401; UCN-02; (5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; 7-Hydroxystaurosporine; 7-hydroxystaurosporine (UCN-01)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Non-small cell lung cancer [ICD11:2C25] | Phase 2 | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C28H26N4O4
|
|||||
| Canonical SMILES |
CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)C(NC6=O)O)NC)OC
|
|||||
| InChI |
InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1
|
|||||
| InChIKey |
PBCZSGKMGDDXIJ-HQCWYSJUSA-N
|
|||||
| CAS Number |
CAS 112953-11-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 482.5 | Topological Polar Surface Area | 89.7 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
499504
,597067
,828000
,828774
,829609
,7890973
,7980340
,11417349
,12014075
,14834856
,14859145
,43128463
,46392797
,46517284
,49965093
,53789227
,57318623
,75855760
,93575990
,103073266
,103083413
,104252674
,117623524
,131269002
,134338729
,135030252
,139892065
,143298032
,163685599
,198960442
,227749464
,247172087
,249565590
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00098956) 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | |||||
| 2 | Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.